Jinyouli (pegfilgrastim biosimilar) / CSPC Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jinyouli (pegfilgrastim biosimilar) / CSPC Pharma
ChiCTR1800019516: A randomized controlled clinical trial for Jinyouli (PEGylated recombinant human granulocyte stimulating factor injection, PEG-rhG-CSF) in preventing febrile neutropenia in breast cancer patients

Not yet recruiting
4
370
 
Jinyouli (PEG-rhG-CSF) was injected subcutaneously 48 hours after the end of chemotherapy ;Jinyouli (PEG-rhG-CSF) was injected subcutaneously 24 hours after the end of chemotherapy
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, CSPC Baike (Shandong) Biological Pharmaceutical Co., Ltd.
Breast Cancer
 
 
ChiCTR1900027961: Real-world study for pegfilgrastim(Jinyouli) in preventing neutropenia after chemotherapy in patients with ovarian cancer

Not yet recruiting
4
500
 
After 24 hours of chemotherapy, and 12 days before the next cycle of chemotherapy, subcutaneous injection of Jinyouli (PEG-rhG-CSF) 6mg
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, China Shijiazhuang Pharmaceutical Company (CSPC) Baike (Shandong) Biopharmaceutical Co. Ltd.
ovarian cancer
 
 
ChiCTR1900024494: A perspective, single-arm trial for evaluating efficacy and safety of Jinyouli (PEG-rh-CSF) to prevent neutropenia with radiation and chemotherapy of TP regimen for cervical cancer

Not yet recruiting
4
52
 
rhG-CSF
Beijing Cancer Hospital; Beijing Cancer Hospital, none
cervical cancer
 
 
NCT04497688: Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Recruiting
N/A
104
RoW
PEG-rhG-CSF
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., Hebei Medical University Fourth Hospital
Non Hodgkin's Lymphoma
09/20
10/20

Download Options